CCN2 and glaucoma: The marketed drug candidates, such as Latanoprost, Netarsudil mesylate, and Prednisone, have been approved for the treatment of CTGF-related glaucoma, hypertensive eye disease, corneal edema, Duchenne muscular dystrophy, prostate cancer, and autoimmune hepatitis [141,142].